One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis

BRITISH JOURNAL OF DERMATOLOGY

WILEY

1. Janssen Pharmaceutica NV
2. Janssen